| Literature DB >> 23150997 |
Roger G Owen1, Robert A Kyle, Marvin J Stone, Andy C Rawstron, Veronique Leblond, Giampaolo Merlini, Ramon Garcia-Sanz, Enrique M Ocio, Enrica Morra, Pierre Morel, Kenneth C Anderson, Christopher J Patterson, Nikhil C Munshi, Alessandra Tedeschi, Douglas E Joshua, Efstathios Kastritis, Evangelos Terpos, Irene M Ghobrial, Xavier Leleu, Morie A Gertz, Stephen M Ansell, William G Morice, Eva Kimby, Steven P Treon.
Abstract
This report represents a further update of the consensus panel criteria for the assessment of clinical response in patients with Waldenström macroglobulinaemia (WM). These criteria have been updated in light of further data demonstrating an improvement in categorical responses with new drug regimens as well as acknowledgement of the fact that such responses are predictive of overall outcome. A number of key changes are proposed but challenges do however remain and these include the variability in kinetics of immunoglobulin M (IgM) reduction with different treatment modalities and the apparent discrepancy between IgM and bone marrow/tissue response noted with some regimens. Planned sequential bone marrow assessments are encouraged in clinical trials.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23150997 DOI： 10.1111/bjh.12102
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998